Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5% – Here’s Why

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)’s stock price dropped 7.5% during mid-day trading on Monday . The company traded as low as $7.79 and last traded at $7.7550. Approximately 150,801 shares traded hands during trading, a decline of 82% from the average daily volume of 825,161 shares. The stock had previously closed at $8.38.

Analyst Upgrades and Downgrades

FULC has been the topic of a number of research reports. JPMorgan Chase & Co. started coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 target price on the stock. Stifel Nicolaus set a $25.00 price objective on Fulcrum Therapeutics in a research report on Monday, December 8th. Truist Financial set a $17.00 target price on Fulcrum Therapeutics in a research report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and issued a $23.00 target price (up from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Finally, Leerink Partners reissued an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Fulcrum Therapeutics Stock Performance

The company has a market capitalization of $531.80 million, a PE ratio of -6.75 and a beta of 3.23. The company has a 50 day moving average price of $10.58 and a 200 day moving average price of $9.52.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). On average, equities analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares in the company, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.00% of the stock is owned by insiders.

Institutional Trading of Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of FULC. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Fulcrum Therapeutics in the 4th quarter valued at about $30,000. Meeder Asset Management Inc. bought a new position in Fulcrum Therapeutics in the fourth quarter worth about $39,000. Quarry LP acquired a new position in Fulcrum Therapeutics in the third quarter valued at approximately $35,000. Persistent Asset Partners Ltd bought a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at approximately $75,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares during the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.